---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-100628"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:37:22.360702+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# NeuroPace director Greg Garfield will not seek reelection; Board to shrink to seven

## Summary
- Greg Garfield informed NeuroPace on April 11, 2023 he will not stand for reelection as director.
- Garfield's departure is not due to any disagreements with NeuroPace's operations, policies or practices.
- Board intends to reduce size from eight to seven directors effective as of the Annual Meeting.

## SEC filing metadata
- accession: 0001193125-23-100628
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312523100628/0001193125-23-100628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312523100628/d297084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-100628
- JSON: https://secwatch.observer/filing/0001193125-23-100628.json
- Plain text: https://secwatch.observer/filing/0001193125-23-100628.txt

## Key facts
- Executive change
  Greg Garfield departed as director at NeuroPace Inc.
  - Action: will not stand for reelection
  - Role: director
  source text: On April 11, 2023, Greg Garfield notified NeuroPace, Inc. that he will not stand for reelection as a director to the Board of Directors (the “Board”) of NeuroPace, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000119312523100628/0001193125-23-100628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.